A network meta-analysis was conducted to compare the efficacy and safety of various oral vitamin D–based combination therapies against vitamin D3 monotherapy in children with nutritional rickets. The study pooled data from 10 randomized controlled trials encompassing a total of 867 children. The primary outcome assessed was serum 25-hydroxyvitamin D levels, while secondary outcomes included bone-specific alkaline phosphatase, serum calcium, serum phosphate, and adverse events. The study phase and specific setting were not reported in the available data.
Results demonstrated that vitamin D-based combination therapies were associated with significantly improved serum 25-hydroxyvitamin D levels compared to monotherapy. Additionally, these combination regimens led to a reduction in bone-specific alkaline phosphatase and an increase in both serum calcium and phosphate concentrations. Subgroup analysis revealed significantly greater benefits among term infants compared to preterm infants, with a p-value less than 0.001. Regarding safety, the analysis found no increased risk of adverse events with the combination therapies, though specific data on serious adverse events, discontinuations, and overall tolerability were not reported.
The robustness of these findings was confirmed through sensitivity analyses. However, the authors explicitly state that head-to-head evidence comparing different vitamin D-based combinations remains limited. They emphasize that further high-quality trials are required to strengthen the evidence base. Consequently, while the data supports individualized, goal-oriented combination strategies, the certainty of the evidence is constrained by the current limitations in direct comparative data.
View Original Abstract ↓
BackgroundNutritional rickets is a major pediatric bone disorder closely associated with vitamin D deficiency. Clinical practice has gradually shifted from vitamin D monotherapy toward combination regimens aiming to enhance therapeutic efficacy through complementary mechanisms. However, head-to-head evidence comparing different vitamin D-based combinations remains limited, and their relative efficacy and safety rankings are unclear.ObjectiveTo systematically compare the efficacy and safety of different oral vitamin D–based combination therapies for nutritional rickets in children and to provide evidence-based guidance for clinical decision-making.MethodsWe conducted a systematic search of PubMed, Embase, the Cochrane Library, Web of Science, CNKI, Wanfang, and VIP databases, followed by a Bayesian network meta-analysis. The study protocol was prospectively registered in PROSPERO (CRD420251029274).ResultsTen randomized controlled trials involving 867 children were included, comparing nine vitamin D–based combination regimens with vitamin D3 monotherapy. Pairwise meta-analyses showed that combination therapies significantly improved serum 25-hydroxyvitamin D levels, reduced bone-specific alkaline phosphatase, and increased serum calcium and phosphate concentrations, without an increased risk of adverse events. Subgroup analyses indicated significantly greater benefits among term infants than preterm infants (P < 0.001). Network meta-analysis revealed distinct relative advantages across outcomes among different combinations. Sensitivity analyses confirmed the robustness of the findings.ConclusionVitamin D-based combination therapies are overall more effective than vitamin D3 monotherapy in improving biochemical markers of bone metabolism in children with rickets, without compromising safety. Different regimens exhibit outcome-specific advantages, with clearer benefits observed in term infants. These findings support individualized, goal-oriented combination strategies, although further high-quality trials are required to strengthen the evidence base.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420251029274.